{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:15:54Z","timestamp":1746321354578,"version":"3.38.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ciprofloxacin (CIP) is effective against many Gram-negative pathogens and penetrates well into respiratory secretions and pulmonary tissues, thus making it useful for treating respiratory infections in patients with cystic fibrosis (CF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A 13-year-old patient with severe CF and an acute respiratory exacerbation from multidrug-resistant <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> was treated with 700 mg of CIP every 8 hours. Bronchial secretions confirmed that <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> was sensitive to high doses of CIP. Pharmacokinetic monitoring using 2 blood samples estimated the AUC24 at 50 hours*mg\/L. This led to an increase in CIP dosage to 850 mg three time a day (TID), then to 1000 mg TID, and finally to 1200 mg every 6 hours.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>CIP pharmacokinetics can vary significantly, particularly in patients with CF due to increased clearance, ultimately resulting in shorter half-lives and higher risks of therapeutic failure and resistance. Therapeutic drug monitoring helps when adjusting dosages to maintain effective blood concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case underscores the role of therapeutic drug monitoring in optimizing CIP dosing for patients with CF and highlights the necessity for close collaboration between clinicians and pharmacologists to ensure effective antibiotic exposure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001267","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:00:34Z","timestamp":1731510034000},"page":"189-192","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ciprofloxacin Dosage Optimization in Cystic Fibrosis Through Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"47","author":[{"given":"Hamza","family":"Sayadi","sequence":"first","affiliation":[{"name":"Service of Pharmacology, Toxicology and Pharmacovigilance Department, CHU Dupuytren, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeleen","family":"Fromage","sequence":"additional","affiliation":[{"name":"Service of Pharmacology, Toxicology and Pharmacovigilance Department, CHU Dupuytren, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Service of Pharmacology, Toxicology and Pharmacovigilance Department, CHU Dupuytren, Limoges, France;"},{"name":"Pharmacology & Transplantation, Inserm U1248, Univ. Limoges, CHU Dupuytren, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Languepin","sequence":"additional","affiliation":[{"name":"CRCM Mixte Limousin, Department of Medical Pediatrics, CHU Dupuytren, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Masson-Rouchaud","sequence":"additional","affiliation":[{"name":"CRCM Mixte Limousin, Department of Medical Pediatrics, CHU Dupuytren, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Labriffe","sequence":"additional","affiliation":[{"name":"Service of Pharmacology, Toxicology and Pharmacovigilance Department, CHU Dupuytren, Limoges, France;"},{"name":"Pharmacology & Transplantation, Inserm U1248, Univ. Limoges, CHU Dupuytren, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Service of Pharmacology, Toxicology and Pharmacovigilance Department, CHU Dupuytren, Limoges, France;"},{"name":"Pharmacology & Transplantation, Inserm U1248, Univ. Limoges, CHU Dupuytren, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ppul.23638","article-title":"Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients","volume":"52","author":"Schultz","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1128\/AAC.30.2.260","article-title":"Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients","volume":"30","author":"LeBel","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkg403","article-title":"Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis","volume":"52","author":"Zelenitsky","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jac\/dkq211","article-title":"Support for higher ciprofloxacin AUC 24\/MIC targets in treating Enterobacteriaceae bloodstream infection","volume":"65","author":"Zelenitsky","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/phar.1761","article-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk?","volume":"36","author":"Bidell","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/psp4.12689","article-title":"Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr","volume":"10","author":"Le Louedec","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/AAC.47.10.3170-3178.2003","article-title":"Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections","volume":"47","author":"Payen","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00228-021-03174-1","article-title":"Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens","volume":"77","author":"Hirt","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/psp4.12467","article-title":"Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial","volume":"8","author":"Elmokadem","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF01967005","article-title":"Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal","volume":"10","author":"LeBel","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.37.6.1289","article-title":"Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus","volume":"37","author":"Fung-Tomc","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250314","first-page":"120","article-title":"Safety of ciprofloxacin. A review","volume":"60","author":"Rahm","year":"1989","journal-title":"Scand J Infect Dis Suppl"},{"issue":"suppl D","key":"R15-20250314","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/26.suppl_D.31","article-title":"Safety profile of the quinolones","volume":"26","author":"Stahlmann","year":"1990","journal-title":"J Antimicrob Chemother"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:00:37Z","timestamp":1741964437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001267","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"2024-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}